EUVIMEDEUVIMED entdecken
Crossref

Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD

Mei-Hsuan Lee iD, Maria Stepanova, Michael Estep, Yan-Ling You, Xia-Rong Liu, Leyla de Avila, Brian Lam, Ming-Lung Yu iD, Zobair M Younossi iD

Liver International · 2026-06 · 46 (6)

DOI: 10.1111/liv.70675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 07.05.2026. Verfasst von Mei-Hsuan Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH/MASH Council (GNC), Washington, DC, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Membrane Proteins, Lipase, Fatty Liver. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Science and Technology Council, Taipei, Taiwan, National Health Research Institute, Chunan, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction–associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. Although genetic variants are linked to MASLD progression, whether their associations with fibrosis severity are consistent across clinical contexts remains unclear.

Methods

A cross‐sectional analysis of 6446 individuals with MASLD from a community‐based ( n = 4477) and a tertiary‐care hepatology population ( n = 1969) was conducted. Fibrosis severity was assessed using the fibrosis‐4 (FIB‐4) index. Associations between MASLD‐related genetic variants ( PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738) and fibrosis were evaluated using multivariable logistic regression within each population.

Results

Advanced fibrosis was more prevalent in the tertiary‐care population than in the community‐based population (FIB‐4 > 1.30: 34.5% vs. 41.2%; FIB‐4 ≥ 3.25: 8.4% vs. 0.4%). PNPLA3 rs738409 showed consistent associations with fibrosis severity in both populations, with markedly stronger effects in the tertiary‐care setting. In the community‐based population, the GG genotype was associated with significant fibrosis (FIB‐4 > 1.30; adjusted OR 1.28; 95% CI, 1.03–1.60; P for trend = 0.015), but not with higher thresholds. In contrast, in the tertiary‐care population, the GG genotype was strongly associated with FIB‐4 > 1.30 (OR 3.11; 95% CI, 2.23–4.34), and FIB‐4 ≥ 3.25 (OR 4.17; 95% CI, 2.60–6.67; all P for trend < 0.001). TM6SF2 rs58542926 showed modest associations only in the community‐based population, while MBOAT7 rs641738 was not associated with fibrosis severity.

Conclusions

Genetic associations with fibrosis in MASLD appear to be context dependent. PNPLA3 rs738409 shows consistent but markedly greater effect sizes in tertiary‐care settings, suggesting that clinical and metabolic context may play an important role in modulating genetic risk beyond ancestry alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisMembrane ProteinsLipaseFatty LiverHumansCross-Sectional StudiesFemaleAcyltransferasesSeverity of Illness IndexMalePhospholipases A2, Calcium-IndependentMiddle AgedLogistic ModelsPolymorphism, Single NucleotideAgedAdultGenetic Predisposition to DiseaseMultivariate AnalysisGenetic VariationTertiary Care Centers

Substanzen

Membrane ProteinsLipaseAcyltransferasesPhospholipases A2, Calcium-IndependentPNPLA3 protein, humanTM6SF2 protein, humanMBOAT7 protein, human

Autor:innen und Institutionen

  • The Global NASH/MASH Council (GNC), Washington, DC, USA.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Center of Hepatitis Research, College of Medicine and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Mei-Hsuan Lee, Ming-Lung Yu, Zobair M Younossi

Förderung

  • National Science and Technology Council, Taipei, Taiwan
  • National Health Research Institute, Chunan, Taiwan

Zitieren

APA

Lee, M. H., Stepanova, M., Estep, M., You, Y. L., Liu, X. R., de Avila, L., Lam, B., Yu, M. L., & Younossi, Z. M. (2026). Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD. Liver International, 46(6). https://doi.org/10.1111/liv.70675

Vancouver

Lee MH, Stepanova M, Estep M, You YL, Liu XR, de Avila L, et al. Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD. Liver International. 2026;46(6). doi:10.1111/liv.70675

BibTeX
@article{Lee2026,
  author = {Lee, Mei-Hsuan and Stepanova, Maria and Estep, Michael and You, Yan-Ling and Liu, Xia-Rong and de Avila, Leyla and Lam, Brian and Yu, Ming-Lung and Younossi, Zobair M},
  title = {Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1111/liv.70675}
}
Kostenlos starten →